Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2017 Financial Results
Q4 revenue $4.9M up 33%. Full year 2017 revenue $17.1M up 42%. WALTHAM, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended December 31, 2017 . The Company develops and markets novel therapies, based on
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2017 Financial Results Conference Call
WALTHAM, Mass. , Jan. 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its fourth quarter and full year 2017 financial results before the opening of the market on January 25, 2018. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
WALTHAM, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, involving Quell ®  Wearable Pain Relief Technology™.
View HTML
Toggle Summary NeuroMetrix Reports Preliminary 2017 Financial Highlights
WALTHAM, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported preliminary financial highlights for the fourth quarter and for the full year 2017. GAAP revenue for the fourth quarter of 2017 is estimated at approximately $4.9 million in comparison with $3.7
View HTML
Toggle Summary NeuroMetrix CEO to Participate in CES 2018 Panel on Opioid Crisis
WALTHAM, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D ., Ph.D., President and Chief Executive Officer, will participate in a panel at the Digital Health Summit at CES 2018.  The panel, “The Vicious Spiral: How Will the Opioid
View HTML
Toggle Summary NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences
WALTHAM, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the 10 th Annual Biotech Showcase 2018 Conference at the Hilton San Francisco Union Square on Monday,
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell ® device usability by improving performance for users that maintain an active
View HTML
Toggle Summary NeuroMetrix Closes $3.5 Million Equity Offering
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per
View HTML
Toggle Summary NeuroMetrix Reports Q3 2017 Financial Results
Overall revenue of $3.5M is up 5% year-over-year Quell shipments of 15.6K devices are up 29% year-over-year Quell shipments of 28.7K electrode reorders are up 99% year-over-year Capital structure was simplified with 86% of outstanding warrants retired WALTHAM, Mass.
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19,
View HTML